University of Texas Medical Branch and GenoLogics to Develop a Biomedical Informatics Solution
News Aug 19, 2008
GenoLogics has announced that the Sealy Center for Molecular Medicine at the University of Texas Medical Branch at Galveston (UTMB) has selected GenoLogics to collaborate on developing an integrated biomedical software solution.
The Sealy Center for Molecular Medicine (SCMM) is an interdisciplinary research center at UTMB and is part of the newly formed Institute for Translational Sciences (ITS). The mission of the SCMM is to serve as a focal interface between clinical and basic scientists, addressing UTMB’s strategic plan for personalized medicine.
“The GenoLogics vision to help clients conduct translational research by developing informatics solutions designed for this purpose was completely aligned with the center’s strategic plan to connect our clinical and basic research areas,” said Dr. Allan Brasier, Director, Sealy Center for Molecular Medicine at UTMB.
“In order to enable our goal for personalized medicine, we decided to collaborate with GenoLogics to deploy a biomedical solution that will begin with user-friendly software to efficiently and effectively manage our biospecimens. Investing in a biomedical informatics solution that can also connect to our research data is going to assist the Center with attracting future funding such as the Clinical and Translational Science Awards.”
The Sealy Center for Molecular Medicine is focused on understanding cell stress response pathways using high-throughput systems-based approaches. The biomarkers program is developing new tools to study and classify human diseases at a molecular level, allowing the prediction of individual susceptibility to disease. This research program in personalized medicine will allow the center to make better diagnostics for common medical diseases such as asthma, cancer, diabetes and degenerative diseases.
“In order to validate our biomarkers for common diseases, we needed to exchange information from clinical to research domains, “ said Dr. Kevin Rosenblatt, Director for Biomarker Discovery, Sealy Center for Molecular Medicine. “This can only be done with a biomedical informatics solution that not only tracks our biospecimens, but also the clinical annotations and then connects to the data being generated in our research labs. The GenoLogics Biomedical Informatics solution will have this unique capability to bring it all together in a single platform.”
GenoLogics launched its Biomedical Informatics software solution to address the needs of translational research initiatives. The solution allows clients to track prospective studies, collect patient data at remote sites, provide biospecimen and clinical annotations management and facilitate researchers querying on clinical information and requesting samples. The solution is comprised of five integrated products: BioVault for biospecimen management; BioChronicle for clinical annotations management; BioQuest to enable Web access; BioSphere for study management; and BioSource for electronic patient questionnaires.
“As we develop our new biomedical informatics product suite, it’s important to gain the real-world experience of leading organizations such as the Sealy Center for Molecular Medicine,” says James DeGreef, VP Market Strategy for GenoLogics.
“Their input into the design and development of the biospecimen and clinical annotations products will be invaluable, as well as to the deployment of our web query portal as they look to centralize the management of a number of physically separate biobanks across their research enterprise.”
Inside cells, where DNA is packed tightly in the nucleus and rigid proteins keep intricate transport systems on track, some molecules can simply self-organize, find one another in crowded spaces, and quickly coalesce into droplets. Now, new research shows how proteins that organize into liquid droplets inside cells make certain biological functions possible.
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE